Director/PDMR Shareholding - amendment
This is a correction of the announcement 2276R from 7.00 on 18.08.2010. Reason for the correction: the number of shares acquired for each director was incorrect. The corrected version is set out below.
Cyprotex PLC ("Cyprotex" or the "Company")
Macclesfield, UK - Cyprotex PLC (LSE: CRX), a Contract Research Organisation (CRO) specialising in the preclinical ADME assessment of drug candidates, was informed on 17 August 2010 that certain directors acquired ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") on 17 August 2010. Details of the dealings are set out below:
|
Name |
Title |
Price |
Shares acquired |
Total interest following dealing |
% of total issued share capital |
|
Steve Harris |
Chairman |
3.50 |
707,142 |
1,507,142 |
0.67 |
|
Anthony Baxter |
CEO |
3.50 |
226,285 |
1,067,685 |
0.48 |
|
John Dootson |
CFO |
3.50 |
589,285 |
589,285 |
0.26 |
|
Katya Tsaioun |
CSO |
3.50 |
1,767,857 |
24,133,006 |
10.79 |
|
Douglas Bates |
CMO |
3.50 |
5,303,571 |
27,668,719 |
12.37 |
For further information please contact:
|
Cyprotex PLC |
Tel: +44 1625 505 100 |
|
Dr. Anthony Baxter, Chief Executive Officer |
|
|
|
|
|
|
|
|
Singer Capital Markets Ltd |
Tel: +44 203 205 7500 |
|
Shaun Dobson |
|
|
Claes Spång |
|
|
Financial Dynamics |
Tel: +44 207 831 3113 |
|
Ben Brewerton |
|
|
Ben Atwell |
|
|
Mo Noonan |
Telephone:
Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683
Email:
enquiries@cyprotex.com